The goal of this clinical trial is to investigate whether intravenous injection of tilofiban can reduce microembolism in patients with unruptured intracranial aneurysms after Stent-Assisted Coil Embolization.The main questions it aims to answer are:

• Is it safe to inject tirofiban intravenously during interventional treatment of intracranial aneurysms？
• What dose of tirofiban is safe and effective?

We aim to reduce microembolism in patients with unruptured intracranial aneurysms after Stent-Assisted Coil Embolization.

Inclusion Criteria:

• Age was between 18 and 75 years old;
• Unruptured aneurysm with surgical indications;
• Stent assisted coil embolization treatment was received ;
• The patient was willing to receive intervention treatment.

Exclusion Criteria:

• Complicated with hemorrhagic cerebrovascular diseases such as cerebral vascular malformations and moyamoya disease or their medical history;
• Recent (within 1 year) bleeding symptoms such as gastrointestinal bleeding, clinically significant urinary/reproductive tract bleeding, and skin blueness;
• Dissecting aneurysm, pseudoaneurysm, and bullous aneurysm;
• A known history of coagulation disorders, platelet abnormalities, or thrombocytopenia; 5. Platelet count less than 150 × 109/L；
• A history of major surgical procedures or severe physical trauma within one month;
• Severe uncontrolled hypertension (systolic blood pressure>160mmHg and/or diastolic blood pressure>100mmHg);
• Hemorrhagic retinopathy;
• Chronic hemodialysis;
• Renal insufficiency.

Blinding all personnel who may interfere with the trial results, such as Participant, Care Provider, Investigator and Outcomes Assessor